Bionxt Solutions Inc.
Commented by Stefan Feulner on July 25th, 2023 | 09:45 CEST
Sartorius, BioNxt Solutions, CENIT AG - Attack from the Second Row
While some of the big caps have already reached new highs in the current stock market year 2023, many undiscovered second-tier stocks are still a long way off. At the same time, companies, most of which rely on disruptive technologies, possess powerful potential. If the ambitious goals are achieved, investors can expect above-average returns.
Read
Commented by Juliane Zielonka on July 21st, 2023 | 07:20 CEST
BioNxt Solutions, Morphosys, Palantir - Innovative therapies for Parkinson's, cancer and soaring with AI
There are exciting developments in the biotech industry. Thanks to innovative AI technologies, companies like BioNxt Solutions bionxt.com/investors can analyze medical data faster and develop an innovative medical patch that provides Parkinson's patients with faster symptom relief. This patch carries the active ingredient rotigotine and has enormous market opportunities worldwide. Blockbuster-level market opportunities are emerging at Morphosys with regard to its compound pelabresib for the treatment of a rare form of blood cancer. The Phase III trial is expected to deliver results earlier than expected, and analysts see promising opportunities for the drug. According to a study by Bristol Myers Squibb, about 1.85 million new cases of blood cancer are expected worldwide in 2040. Deutsche Bank rated the stock "hold," driving the price up 4.9% this week. Also pushing upward is Palantir. The US company is getting into the drone business thanks to a partnership with Canada's Airmatrix.
Read
Commented by André Will-Laudien on July 5th, 2023 | 07:55 CEST
666% rally in 5 years - can Nucera do even more? BioNTech, BioNxt Solutions, and Plug Power could be the winners!
The story of the Mainz-based biotech company BioNTech has set a precedent over the last 5 years. With a remaining gain of 666%, it still ranks among the best performers on the German stock market, even after a 75% price decline. Such movements usually take place on the NASDAQ, where it is easy for highly innovative technology or biotech stocks to raise the necessary growth capital. But not every stock market story is so positive. We go on a pearl diver's journey.
Read
Commented by Armin Schulz on June 26th, 2023 | 09:20 CEST
Bayer, BioNxt Solutions, BioNTech - Biotech facing a rebound?
Due to the Corona pandemic, the pharmaceutical and biotech sector received a lot of attention. Many investors invested too late and could hardly benefit from the significant upward movements. After the hype, a sense of disillusionment set in. The vaccine manufacturers felt the effects because as soon as the pandemic subsided, the stock market also went down. Large and small companies experienced sell-offs, with some trading below their cash reserves. These low prices led to a wave of takeovers. Most recently, Novartis snapped up the biotech company Chinook for up to USD 3.5 billion. Therefore, today, we look at three companies from the healthcare sector.
Read
Commented by Fabian Lorenz on June 21st, 2023 | 08:40 CEST
Biotech comeback! Profit with BioNTech, Morphosys and BioNxt Solutions
Biotech shares have not been among the favourites on the stock market in recent months. After the Corona hype, they were overshadowed by BigTech and especially AI. Sartorius, BioNTech and Co. have corrected strongly. But in the meantime, there are strong signs of a comeback - led by Morphosys. The share of the German biotech veteran has doubled since the beginning of April. MediGene and Evotec have also recorded price jumps. Are BioNTech and BioNxt Solutions next? Morphosys also continues to be praised by analysts. But Goldman Sachs wants to end the party.
Read
Commented by Nico Popp on June 12th, 2023 | 08:00 CEST
Disruption! From now on, everything will be different: PayPal, BYD, BioNXt
What is now called disruption in the startup scene has always existed. It refers to creative destruction, cutting old ties and rethinking things from the ground up. Companies that create marketable products in this way have an edge over the competition - and score points on the market with their uniqueness. We present three titles.
Read
Commented by Stefan Feulner on June 6th, 2023 | 07:15 CEST
MediGene, BioNTech, BioNxt Solutions - New opportunities after the correction
Acquisitions by big pharma were increasingly expected in the biotechnology sector last year, but these largely failed to materialize. However, this trend could accelerate in the current year. On the one hand, pharmaceutical companies, such as the vaccine manufacturer Pfizer, have deep pockets and need new innovations for their product portfolio. On the other hand, second-tier stocks are attractive targets due to the strong correction.
Read
Commented by Juliane Zielonka on June 1st, 2023 | 09:30 CEST
BioNxt Solutions, Bayer, Palantir - AI is dominating the market at breathtaking speed and ensuring high returns
Tech investors have suffered heavy losses over the past year. But tech in pharma and security in defence enables entirely new future scenarios whose precise developments are worth examining more closely. For example, gentler and more effective new ways that benefit patients are emerging in the drug delivery market. At the forefront is the Company BioNxt Solutions, which specializes in innovative transdermal patches whose active ingredients literally go under the skin. In Germany, the biotech company cooperates with a German pharmaceutical partner. New times are now dawning for Bayer as well. Under the new reign of CEO Bill Anderson, digital health seems to have finally found its positioning in the Consumer Health division. There, the Company is to cooperate with exciting start-ups that collect and analyze consumer data. When it comes to networking and interpreting data using AI, one company in particular stands out at the moment. Palantir is moving out to "dominate the entire market." How? Find out in the comments below.
Read
Commented by André Will-Laudien on May 16th, 2023 | 09:45 CEST
BioNTech, Bayer, BioNxt, Formycon - The next biotech wave is rolling in - select carefully now!
Even after Corona, the biotech sector remains an interesting investment sector because it is still important to keep an eye on the major widespread diseases. For many companies, this will probably mean a longer waiting game for investors. In addition to the promising research approaches and milestone plans, the cash reserves of these companies are also important. While having ample funding can lead to quick progress in the laboratory, it is crucial to have the necessary liquidity. In refinancing, however, things have become a little frostier since the rise in interest rates. Which companies should be put under the microscope?
Read
Commented by Armin Schulz on May 8th, 2023 | 08:10 CEST
MorphoSys, BioNxt Solutions, Pfizer - After the pandemic is before the pandemic
No sooner has the Corona pandemic officially ended than the West Nile virus is knocking on Germany's door. According to Christian Drosten, it could spread in Germany via the mosquitoes that transmit the virus. Experts are already predicting the next pandemic, but when it will come remains uncertain. But other diseases such as cancer, malaria and antibiotic resistance are also on the rise. These diseases are exacerbated by food production and ageing populations, especially in Western industrialized nations. It is here where biotech and pharmaceutical companies are needed to alleviate people's suffering. We look at three such companies today.
Read